United States Duchenne Muscular Dystrophy Therapeutics Market
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market is projected to reach US$ 11.31 billion by 2033, growing at a CAGR of 9.24% from US$ 5.31 billion in 2025. DataM Intelligence's latest research highlights significant growth opportunities driven by advancements in gene-targeted therapies, increased regulatory support, and growing investments from pharmaceutical companies. Key players like Sarepta Therapeutics, PTC Therapeutics, and Roche are actively expanding their research and commercialization efforts in this high-growth sector.
BofA reiterates Buy on PTC Therapeutics stock citing Sephience launch momentum
BofA Securities has reiterated a Buy rating and a $93.00 price target for PTC Therapeutics (NASDAQ:PTCT), citing positive momentum from the Sephience launch and confidence in its peak sales potential of over $2 billion. This optimism is supported by PTC's expected profitability this year, with projected earnings of $1.20 per share. The company's CEO, Dr. Matthew Klein, reported strong U.S. Sephience launch demand, broad activation in PKU centers, and a stable prescription rate.
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,812 Shares
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,812 shares of the company's stock on May 15th at an average price of $72.18, totaling approximately $202,970. This transaction was conducted under a pre-arranged Rule 10b5-1 plan, and Boulding retains ownership of 105,212 shares. The biopharmaceutical company recently reported better-than-expected quarterly earnings, with revenue up 43.5% year-over-year, and analysts currently maintain a "Moderate Buy" rating for the stock.
PTC Therapeutics (PTCT) CLO exercises options and sells 2,812 shares under 10b5-1 plan
Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics (PTCT), exercised stock options for 2,812 shares at $25.69 per share and subsequently sold these shares in open-market transactions at weighted average prices of $72.67 and $72.08. These transactions were executed under a pre-arranged Rule 10b5-1 plan. Following the sales, Boulding directly holds 105,212 Common Stock shares and 19,689 stock options.
PTC Therapeutics’ SWOT analysis: stock gains on rare disease drug launch
PTC Therapeutics (NASDAQ:PTCT) has seen its stock gain following the successful launch of Sephience, its oral therapy for Phenylketonuria, which exceeded early expectations and led to raised financial guidance for 2025. Despite strong revenue growth driven by Sephience, the company faces near-term profitability challenges with a projected decline in EPS for the next fiscal year, though analysts expect profitability for the current year. The company's future growth hinges on sustained Sephience adoption, pipeline development for other rare diseases, and navigating skepticism around Sephience's mechanism of action.
PTC Therapeutics (PTCT) CEO earns 12,500 RSUs, sells 12,572 shares for tax withholding
PTC Therapeutics CEO Matthew B. Klein was awarded 12,500 performance-based Restricted Stock Units (RSUs) on May 13, 2026, following the certification of a pre-established milestone. Of these, 6,250 shares vested immediately, and the remaining 6,250 will vest in May 2027. Subsequently, on May 14, 2026, Klein sold 12,572 shares in open-market transactions to cover tax withholding obligations associated with the RSU vesting, retaining a direct ownership of 393,998 shares in the company.
TD Bank holds 3,025,945 PTC Therapeutics shares (NASDAQ: PTCT) — 3.7%
TD Bank has reported beneficial ownership of 3,025,945 shares of PTC Therapeutics (NASDAQ: PTCT), which constitutes 3.7% of the company's common stock. This information was disclosed in an Amendment No. 1 to a Schedule 13G/A SEC filing, signed on May 15, 2026, indicating TD Bank holds sole voting and dispositive power over these shares. The filing specifies that this ownership is less than 5% of the class.
Janus Henderson Group (NASDAQ: PTCT) holds 8.7% of PTC Therapeutics (7.19M shares)
Janus Henderson Group plc has reported a beneficial ownership of 7,193,433 shares in PTC Therapeutics, representing an 8.7% stake as of March 31, 2026. This ownership is held across multiple Janus Henderson asset management entities for client-managed portfolios, with shared voting and dispositive power. The asset managers disclaim rights to dividends or sale proceeds, indicating that beneficial ownership arises from discretionary management for their clients.
PTC Therapeutics CEO Matthew B. Klein sells $917,153 in stock
Matthew B. Klein, CEO of PTC Therapeutics, sold $917,153 worth of common stock on May 14, 2026, after acquiring 12,500 shares as restricted stock units. This sale followed a period of strong stock performance, though InvestingPro views the company as slightly overvalued. The company recently reported strong Q1 2026 financial results, surpassing analyst expectations, and received an upgrade to Buy from TD Cowen.
Matthew Klein sells PTCT shares; restricted stock vests (PTCT)
Matthew Klein, an insider at PTC Therapeutics (PTCT), conducted three sales of common stock in early 2026, totaling $883,971.25. Additionally, 2,572 restricted shares vested on May 13, 2026, as compensation. These transactions were disclosed in a Form 144 SEC filing, indicating routine insider activity.
PTCT (NASDAQ: PTCT) director sells shares; restricted stock vests
A recent Rule 144 SEC filing for PTC Therapeutics (NASDAQ: PTCT) indicates that director Matthew Klein sold a total of 12,883 shares across three transactions between February and April 2026, totaling over $880,000. Additionally, the filing reported two restricted stock vesting events in December 2025, where 9,999 shares became fully owned. These procedural entries notify the market of insider activity and stock vesting.
Mark Elliott Boulding Sells 3,540 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
Mark Elliott Boulding, VP of PTC Therapeutics (NASDAQ:PTCT), sold 3,540 shares of the company's stock on May 8th at an average price of $78.97, totaling approximately $279,554. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan, leaving him with 105,212 shares. The sale follows a strong first-quarter earnings report where the company beat analyst expectations for both EPS and revenue, and analyst sentiment remains largely positive with a "Moderate Buy" consensus rating.
[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity
Mark Elliott Boulding, an Executive VP and CLO at PTC Therapeutics, engaged in an insider transaction involving the exercise of stock options and subsequent sale of common stock on May 8, 2026. He exercised options to acquire 3,540 shares at $46.54 per share and then sold the same number of shares through open-market sales at prices ranging from $78.00 to $79.31 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on September 10, 2025, leaving him with 105,212 direct common stock shares in the company.
Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance
PTC Therapeutics (PTCT) saw its stock rise by 12.5% after reporting better-than-expected Q1 earnings, with revenue of US$272.55 million beating analyst expectations despite a net loss. The company also released positive 24-month interim data for its Huntington’s disease therapy, votoplam, and raised its 2026 product revenue guidance, highlighting the impact of its Sephience launch and advancing neurology pipeline. While strong performance and pipeline progress are positive, investors are cautioned about the company's persistent cash burn and negative shareholders’ equity.
Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance
PTC Therapeutics (PTCT) saw its stock rise by 12.5% after reporting better-than-expected Q1 2026 revenue and earnings, despite a year-over-year decline in revenue and a net loss. The company also released positive 24-month data for its Huntington’s disease therapy, votoplam, and increased its 2026 product revenue guidance, driven by the strong performance of Sephience and its advancing neurology pipeline. While these developments strengthen PTC's investment case, the company remains unprofitable with negative equity, highlighting risks associated with cash burn and potential dilution.
State of New Jersey Common Pension Fund D Sells 19,078 Shares of PTC Therapeutics, Inc. $PTCT
The State of New Jersey Common Pension Fund D reduced its stake in PTC Therapeutics (PTCT) by 43.9% in Q4, selling 19,078 shares and holding 24,402 shares valued at $1.85 million. This occurred despite PTC Therapeutics reporting strong Q1 revenue of $273 million and EPS of -$0.03, both exceeding estimates, leading to a raised full-year 2026 revenue guidance. Analyst sentiment remains mixed but generally constructive, with some firms raising price targets and the stock retaining a "Moderate Buy" consensus.
PTCT Soars As PTC Therapeutics Lifts 2026 Guidance And Beats Earnings
PTC Therapeutics Inc. (NASDAQ: PTCT) experienced a significant 14.27% stock increase due to positive clinical pipeline progress, a strong Q1 earnings beat, and lifted 2026 revenue guidance. The company's Q1 revenue of $272.55M widely surpassed consensus, and its net loss narrowed dramatically. Analysts have upgraded price targets, indicating institutional alignment and a bullish outlook for PTCT.
PTC Therapeutics (PTCT) Huge Q1 Profitability Spike Tests Bullish Earnings Narratives
PTC Therapeutics (PTCT) concluded FY 2025 with mixed results, showing profitability on a trailing twelve-month basis primarily due to an exceptionally strong Q1 2025, which alone contributed US$1.2 billion in revenue and US$866.6 million in net income. This single quarter significantly skews the company's otherwise inconsistent quarterly performance, which includes multiple loss-making periods. While a low P/E ratio and a large DCF gap suggest undervaluation, analysts remain cautious due to forecasted shrinking margins, negative shareholders' equity, and insider selling, prompting investors to scrutinize the sustainability of its profitability and long-term prospects.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2026 Earnings Call Transcript
PTC Therapeutics reported a strong first quarter in 2026, achieving record product revenue of $226 million, largely driven by the successful global launch of their PKU treatment, Sephience, which generated $125 million. The company raised its full-year product revenue guidance to $750-$850 million, with total revenue projected at $1.08-$1.18 billion. PTC also provided updates on its pipeline, including positive interim results for its Huntington's disease program, votoplam, and plans for a new open-label study for vatiquinone in Friedreich’s ataxia.
PTC Therapeutics, Inc. $PTCT Shares Purchased by Comerica Bank
Comerica Bank significantly increased its stake in PTC Therapeutics, boosting its holdings by 3,231.9% to 17,426 shares worth approximately $1.32 million. PTC Therapeutics reported strong Q4 results, exceeding EPS and revenue estimates, and raised its full-year 2026 revenue guidance to $1.1 billion-$1.2 billion, contributing to a "Moderate Buy" consensus rating from analysts. Insider selling by executives Lee Scott Golden and Mark Elliott Boulding was also noted in recent transactions.
PTC Therapeutics (PTCT) Huge Q1 Profitability Spike Tests Bullish Earnings Narratives
PTC Therapeutics (PTCT) experienced a significant profitability spike in Q1 2025, contributing substantially to its trailing twelve-month net income, despite otherwise mixed quarterly results including losses. This reliance on one strong quarter raises questions about the sustainability of its profitability and challenges bullish narratives, especially given negative shareholders' equity and high non-cash earnings. The stock's low P/E ratio and large DCF gap suggest undervaluation, but forecasts for shrinking margins and future earnings decline invite caution.
PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS
PTC Therapeutics (NASDAQ:PTCT) announced strong Q1 earnings, surpassing analyst estimates with an EPS of -$0.03 against a projected -$0.45, and revenue of $272.6 million, exceeding expectations of $218.8 million. The company reported significant year-over-year revenue growth of 43.5% and raised its full-year 2026 guidance, reflecting strong commercial momentum and progress in its pipeline, including accelerating Sephience launch and positive interim data for votoplam. PTC Therapeutics also maintains strong liquidity with $1.89 billion in cash and investments.
PTC Therapeutics Q1 Earnings Call Highlights
PTC Therapeutics reported a record first quarter for product revenue, with total revenue reaching $273 million and product revenue at $226 million. The company raised its full-year 2026 product revenue guidance to $750 million-$850 million, attributing the growth to strong early demand for its PKU treatment, Sephience, which generated $125 million in global revenue. PTC also provided updates on its Duchenne muscular dystrophy (DMD) franchise, royalty revenue from Evrysdi, and pipeline developments for Huntington's disease and Friedreich's ataxia.
PTCT Stock Jumps As Earnings Beat And Drug Data Fuel Bullish Momentum
PTC Therapeutics Inc. (PTCT) stock jumped over 22% after reporting a significant Q1 2026 earnings beat and raising its full-year 2026 revenue guidance. The company's pipeline progress, particularly positive data for its Huntington's drug votoplam and analyst coverage initiation for its phenylketonuria therapy Sephience, contributed to the bullish momentum. Institutional interest is also growing, with a new significant passive stake revealed in a Schedule 13G filing.
PTC Therapeutics lifts 2026 product revenue outlook after Q1 | PTCT Stock News
PTC Therapeutics reported strong Q1 2026 financial results, with total revenue of $273 million and product revenue of $226 million, primarily driven by Sephience sales of $124.6 million. The company has raised its full-year 2026 product revenue guidance to $750–$850 million due to the continued strong global launch momentum of Sephience. Additionally, PTC provided positive clinical updates for its votoplam and vatiquinone programs, including a $50 million milestone payment from Novartis.
New York State Teachers Retirement System Makes New Investment in PTC Therapeutics, Inc. $PTCT
The New York State Teachers Retirement System has initiated a new position in PTC Therapeutics, acquiring 44,637 shares valued at approximately $3.39 million. This investment comes despite significant insider selling in the last quarter, totaling over $8.6 million. PTC Therapeutics recently exceeded analyst expectations for earnings and revenue, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $85.64.
PTC THERAPEUTICS, INC. (PTCT)
The article provides a company profile for PTC THERAPEUTICS, INC. (PTCT). It includes financial data, stock performance metrics, dividend information, analyst ratings, and details on insider transactions.
PTC Therapeutics Q1 Swings to Loss, Revenue Falls
PTC Therapeutics reported a net loss of $133.5 million for the first quarter of 2026, a significant downturn from a net profit of $1.5 million in the same period last year. The company's revenue also declined by 6.7% to $151.7 million. This performance led to a diluted loss per share of $1.76, contrasting with a diluted earnings per share of $0.02 a year ago.
Earnings Flash (PTCT) PTC Therapeutics, Inc. Reports Q1 Revenue $272.6M, vs. FactSet Est of $218.8M
PTC Therapeutics, Inc. announced its Q1 revenue reached $272.6 million, significantly surpassing FactSet's estimated revenue of $218.8 million. The report indicates a strong financial performance for the biopharmaceutical company during the first quarter.
PTC Therapeutics: Q1 Earnings Snapshot
PTC Therapeutics Inc. reported a first-quarter loss of $2.8 million, or 3 cents per share, which was significantly better than the average analyst estimate of a 45 cents per share loss. The biopharmaceutical company also exceeded revenue expectations, posting $272.6 million against an expected $233.7 million. These results indicate a stronger financial performance than anticipated by Wall Street.
Number of shareholders of PTC Therapeutics, Inc. – BX:P91
This article displays the "Number of shareholders" for PTC Therapeutics, Inc. (P91 on BX Swiss) as part of its financial data overview on TradingView. The content is sparse, mainly showing the company ticker and market status, with tables for financial periods, values, and changes. It primarily serves as a placeholder for shareholder data that would be populated in the provided tables.
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Analysts are expecting PTC Therapeutics (PTCT) to report a Q1 quarterly loss of -$0.31 per share and revenues of $236.22 million, representing significant year-over-year declines. The consensus EPS estimate has seen an upward revision of 19.2% in the past 30 days. Investors are advised to look beyond just revenue and EPS, and delve into key metrics such as net product revenue for Emflaza and Translarna, and royalty revenue, which show varying predictions.
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth Narrative Points To Potential Undervaluation
PTC Therapeutics (PTCT), a biopharmaceutical company focusing on rare diseases, is currently showing a potential undervaluation. With a last closing price of $65.49, the stock is indicated to be 25.6% undervalued with a fair value of $88.07, largely driven by its rare disease pipeline and recent product approvals like Sephience. However, investors are cautioned to consider the concentrated product mix and ongoing net losses as potential risks to this valuation.
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics, Inc. announced that its executives will participate in three upcoming investor conferences in May and June 2026: the Bank of America Securities Health Care Conference, the RBC Capital Markets 2026 Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of these presentations will be available on the company's website for 30 days. PTC Therapeutics is a global biopharmaceutical company focused on developing medicines for rare disorders.
PTC Therapeutics (Nasdaq:PTCT) - Stock Analysis
PTC Therapeutics (Nasdaq:PTCT) stock analysis shows it is trading 62.7% below its estimated fair value. The company recently reported positive 24-month interim data for votoplam in Huntington's disease, triggering a $50 million milestone payment from Novartis and new analyst coverage with an "Outperform" rating. However, the company faces risks such as forecasted declining earnings, significant insider selling, and high non-cash earnings.
Three PTC investor conference webcasts start May 12 and stay up 30 days
PTC Therapeutics (NASDAQ: PTCT) executives will present at three investor conferences in May and June 2026: the Bank of America Health Care Conference on May 12, RBC Capital Markets Global Healthcare on May 20, and Goldman Sachs Global Healthcare Conference on June 9. All presentations will be webcast live and archived for 30 days on the company's investor relations website. The company is advancing a pipeline of transformative medicines for rare disorders.
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that its executives will present at three upcoming investor conferences in May and June 2026. The conferences include the Bank of America Securities Health Care Conference, RBC Capital Markets Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of these presentations will be available on the company's investor relations website.
PTC Therapeutics (PTCT) Is Down 5.9% After Strong Votoplam Huntington’s Data - Has The Bull Case Changed?
PTC Therapeutics (PTCT) stock dropped 5.9% despite positive 24-month interim results for its Huntington’s disease drug, votoplam. The data suggests votoplam can slow disease progression and reduce mutant Huntingtin protein, reinforcing its potential as a disease-modifying therapy. However, the company's broader investment narrative still faces challenges from legacy product pressures and high R&D spending, with upcoming Q1 2026 earnings expected to clarify its financial capacity to capitalize on these new findings.
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results
PTC Therapeutics (NASDAQ:PTCT) announced positive 24-month interim results from its PIVOT-HD extension trial for votoplam in Huntington’s disease, showing dose-dependent improvements. Patients on the 10 mg dose experienced a 52% slowdown in disease progression, while the 5 mg dose showed a 28% slowdown. Raymond James initiated coverage with an Outperform rating and a $108 price target, highlighting the potential of Sephience, a new Phenylketonuria medication.
Is PTC Therapeutics a Better Buy Than Eli Lilly?
This article compares PTC Therapeutics (PTCT) and Eli Lilly (LLY), suggesting PTCT offers superior revenue growth, better profitability, and a relatively lower valuation. While LLY has shown higher historical returns, especially over a three-year period, PTCT's fundamental metrics like LTM and 3-year average revenue growth and LTM operating margins are presented as more favorable. The analysis includes a detailed comparison of financial fundamentals and historical market performance for both stocks against the S&P 500.
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
PTC Therapeutics (NASDAQ: PTCT) shares fell after the company released 24-month interim analysis results from its PIVOT-HD long-term extension study for Huntington's Disease. Concerns arose that the FDA might not grant accelerated approval based on the current data set. Despite showing a dose-dependent benefit and favorable safety profile, the stock experienced a bearish short-term trend, trading below its 20-day and 100-day simple moving averages.
PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday
PTC Therapeutics (NASDAQ:PTCT) is scheduled to announce its Q1 2026 earnings on Thursday, May 7th, with analysts forecasting an EPS of -$0.475 and revenue of $219.63 million. This follows a significant miss in the prior quarter, where the company reported an EPS of -$1.67 against an estimated -$0.21. The stock currently trades around $64.55, with analysts holding a "Moderate Buy" rating and an average price target of $84.40.
PTC Therapeutics Stock To $84?
PTC Therapeutics (PTCT) stock has recently dropped by 12.3%, but Trefis believes there's a strong chance of a rebound given its history of recovery post-dips and their current "Attractive" rating. Historically, the stock has shown a median 12-month return of 52% following sharp dips of 20% or more. The analysis suggests PTCT passes basic financial quality checks with strong revenue growth and operating cash flow.
PTC Therapeutics Drops 8.3% Amid Sector-Wide Selling
Shares of PTC Therapeutics, Inc. plunged 8.3% to $64.40 on April 29, 2026, due to a broad downturn across the biotech sector, rather than company-specific news. This decline occurred amid synchronized selling that also impacted peers like TGTX and CAI, suggesting wider market sentiment or sector rotation. Investors are advised to monitor whether this sector weakness continues and to watch for any company-specific catalysts that could differentiate PTC Therapeutics.
Vanguard (NASDAQ: PTCT) holds 4.87M PTC Therapeutics shares
Vanguard Portfolio Management has reported beneficial ownership of 4,871,329 shares of PTC Therapeutics (NASDAQ: PTCT) common stock, which represents 5.88% of the company's class as of March 31, 2026. The filing indicates Vanguard has sole voting power over 66,735 shares and sole dispositive power over all 4,871,329 shares. This ownership position meets the SEC's disclosure threshold for large passive investors and includes holdings across various Vanguard affiliates and funds managed by Vanguard Portfolio Management.
PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing Signals
PTC Therapeutics announced 24-month interim data from its PIVOT-HD study of Votoplam, showing dose-linked slowing of Huntington's disease progression in early-stage patients. The 10 mg dose demonstrated a 52% slowing and the 5 mg dose a 28% slowing on the cUHDRS compared to natural history, with no new safety signals or NfL spikes. The company, in partnership with Novartis, has initiated a Phase 3 INVEST-HD trial, which could lead to accelerated approval discussions.
Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance
This article analyzes PTC Therapeutics' (PTCT) stock valuation amidst its recent pipeline progress and volatile share performance. Using Discounted Cash Flow (DCF) analysis and Price-to-Earnings (P/E) ratios, Simply Wall St suggests PTCT is undervalued, with its DCF model indicating a 59.2% undervaluation compared to its current price. The analysis also explores bull and bear case narratives for the company, highlighting divergent views on its future revenue and profitability.
PTC Therapeutics (NASDAQ: PTCT) shows 52% slowing in HD study
PTC Therapeutics reported positive 24-month interim results from its PIVOT-HD long-term extension study of votoplam for Huntington’s disease. Stage 2 patients demonstrated a dose-dependent slowing of disease progression on the cUHDRS scale, with 52% slowing at the 10 mg dose compared to a natural history cohort. The safety profile remained favorable, and Novartis has initiated a global Phase 3 study (INVEST-HD) for votoplam based on these promising findings.
PTC reports votoplam slowed Huntington’s disease progression by 52%
PTC Therapeutics announced positive interim results from its PIVOT-HD extension study, showing that votoplam significantly slowed Huntington's disease progression in Stage 2 patients. The 10 mg dose led to a 52% slowing, and the 5 mg dose to a 28% slowing, compared to a natural history cohort. This comes as Novartis initiates a global Phase 3 study for votoplam, and analysts offer positive ratings for PTC Therapeutics despite an earlier withdrawal of a New Drug Application for Translarna.
Huntington's drug posts 52% slower decline as Phase 3 starts
PTC Therapeutics announced positive 24-month interim results from its PIVOT-HD extension study for votoplam in Huntington's disease, showing a dose-dependent slowing of disease progression. Stage 2 participants experienced a 52% slower decline at 10 mg and 28% at 5 mg compared to a natural history cohort. Novartis has subsequently initiated the global Phase 3 INVEST-HD study with approximately 770 participants.
